Bruker Announces Novel Molecular Drug Imager Solution at 10th ISSX Meeting

At the 10^th International Society for the Study of Xenobiotics (ISSX) meeting, Bruker today announced the novel Molecular Drug Imager™ solution for pre-clinical drug and metabolite imaging.

MALDI-based tissue imaging for pharmaceutical development has provided researchers with a powerful technique for localizing small molecule drugs and their metabolites, or lipids, within tissue structures, providing key insights into physiological function that were unavailable with previous technologies. With its powerful software and workflow flexibility, the new Molecular Drug Imager solution is poised to take small molecule mass spectrometry imaging (MSI) to the next level by empowering fast, accurate, and thorough evaluation of drug candidates and their metabolites in model tissues and beyond.

For more than a decade, Bruker has provided industry-leading advances in hardware and methods for MALDI-based mass spectrometry imaging. The recently introduced rapifleX™ MALDI-TOF system has set new standards for speed and pixel fidelity for protein imaging and molecular histology research, while the solariX XR™ FTMS system successfully merged MALDI small molecule imaging with Isotopic Fine Structure (IFS) analysis for undisputable molecular formula specificity.

The Molecular Drug Imager leverages the unparalleled power of solariX-based small molecule imaging to provide a comprehensive analysis-to-answer imaging workflow solution to enable pharmaceutical investigators at all levels, from biomarker discovery and validation to drug development studies. Many of the top-25 pharma companies are already using earlier versions of this MSI technology in their pre-clinical efforts to complement or replace expensive workflows, such as Quantitative Whole-Body Autoradiography (QWBA), and to migrate certain animal based pre-clinical models to tissue proxies.